Cancer Pathology: From Biopsy to Final Diagnosis

Cancer pathology is the discipline that converts a small piece of your tissue into a definitive answer about whether cancer is present, what type it is, how aggressive it looks, and which treatments it may respond to. The process involves dozens of hands-on steps and typically takes several days to a couple of weeks, depending on how many specialized tests the sample requires. What most people experience as a nerve-wracking wait is actually a tightly choreographed chain of physical preparation, microscopic analysis, and increasingly sophisticated molecular profiling.

Getting the Tissue Out

Everything starts with a biopsy, and the type of biopsy matters more than most patients realize. The two main approaches for solid tumors are fine-needle aspiration and core-needle biopsy. Fine-needle aspiration uses a thin needle to suction out individual cells, while core-needle biopsy uses a slightly larger needle to extract a small cylinder of intact tissue. That difference is significant: the core sample preserves the architecture of the tissue, letting a pathologist see how cells are arranged relative to each other and the surrounding structures. Fine-needle aspiration, by contrast, yields loose cells on a slide and cannot distinguish between a cancer that has invaded surrounding tissue and one that hasn’t.

For breast lesions, the role of fine-needle aspiration has shrunk considerably because of its lower sensitivity, higher rate of nondiagnostic results, and inability to differentiate in situ from invasive disease. Core-needle biopsy is now the standard diagnostic method for breast masses and establishes a final diagnosis more often than fine-needle aspiration for both benign and malignant lesions.¹ A meta-analysis of salivary gland tumors found an even starker gap: core-needle biopsy reached roughly 99% sensitivity compared with about 68% for fine-needle aspiration, with similarly high specificity for both methods.² Fine-needle aspiration still has a role for cystic lesions, suspected chest-wall recurrences, and lymph node sampling, but when a solid tumor needs a definitive tissue diagnosis, the core needle is the workhorse.

Fixing and Processing the Specimen

Once a tissue sample reaches the lab, the clock starts on preservation. The standard approach is to submerge it in formalin, a formaldehyde-based solution that cross-links proteins and halts decay. This step, called fixation, is critical because it locks the tissue’s cellular detail in place so it can be examined days, weeks, or even years later. The fixed tissue is then dehydrated, cleared of water, and infiltrated with paraffin wax so it can be cut into sections just a few micrometers thick. These ultra-thin slices are mounted on glass slides.

Fixation time is a balancing act. Too little formalin exposure and the tissue degrades during later steps; too much and the chemical cross-linking damages DNA and RNA in the sample. Prolonged formalin fixation has been shown to reduce successful amplification of key genetic markers, meaning over-fixed tissue can become unsuitable for downstream molecular testing.³ Research comparing formalin to ethanol-based fixatives found that formalin-fixed tissue showed a dramatic drop in RNA quality after one week, whereas ethanol-based fixation kept RNA intact for months.⁴ Despite these drawbacks, formalin remains the global default because decades of diagnostic criteria, staining protocols, and reference images are built around it. Labs carefully control soak times, usually targeting somewhere between six and 72 hours depending on the specimen, to preserve both the tissue’s appearance under a microscope and its molecular usefulness.

The H&E Slide

The single most important stain in cancer pathology is hematoxylin and eosin, universally abbreviated H&E. Hematoxylin stains cell nuclei blue-purple; eosin stains the cytoplasm and most extracellular structures pink-red. The result is a two-color map that highlights the fine structures of cells and tissues and has been the cornerstone of surgical pathology diagnosis for over a century.⁵ Under a pathologist’s microscope, this contrast reveals nuclear size and shape, how cells are arranged, whether they are invading surrounding tissue, and how abnormal they look compared to their normal counterparts.⁶

H&E slides are where the initial call of benign versus malignant is made. They are also where the pathologist begins to classify the tumor type and grade. Despite the explosion of molecular tools in recent decades, this simple dye combination remains the starting point for virtually every cancer diagnosis worldwide.

When Surgeons Cannot Wait for Results

Sometimes a pathologist needs to render a verdict while the patient is still on the operating table. Frozen sections make this possible. Instead of the multi-day formalin-paraffin workflow, the tissue is rapidly frozen, cut, stained, and examined within about 20 minutes. Surgeons use frozen-section results to decide whether to widen a resection, remove additional lymph nodes, or change the scope of an operation entirely.

The trade-off is accuracy. Frozen sections produce slides with more artifacts and less detail than permanent sections. A large study across organ systems found that about 2.7% of frozen-section diagnoses did not agree with the final permanent-section result, and another 3.1% were deferred because the pathologist could not make a confident call on the frozen material.⁷ Accuracy varies by organ: breast and skin specimens tend to have low discordance rates, while pancreas and gynecologic specimens are harder to call. For liver and pancreas surgery specifically, one study reported 98.4% overall diagnostic accuracy on frozen sections, with the small number of errors traced to technical, interpretational, and sampling issues.⁸ In ovarian tumors, which are notoriously difficult, frozen-section concordance with the final diagnosis was about 82%, and roughly one in five patients experienced a management change because of the discrepancy.⁹

Grading and Staging

Once a cancer is confirmed, the pathologist assigns a grade and contributes to the stage. These are distinct concepts that answer different questions. Grade describes how abnormal the tumor cells look under the microscope: well-differentiated cells still resemble normal tissue, while poorly differentiated cells have lost most of their normal features. Higher-grade tumors tend to grow faster and behave more aggressively. In breast cancer, histological grade is one of the best-established prognostic factors and has been shown to predict clinical behavior even in the era of molecular subtyping.¹⁰ A study of oral cavity squamous cell carcinoma found that poorly differentiated tumors had worse survival and were more aggressive than well- or moderately differentiated tumors, and that poor differentiation was an independent risk factor for recurrence.¹¹

Staging uses the TNM system, an internationally accepted framework that considers the size and local extent of the primary tumor (T), whether cancer has spread to nearby lymph nodes (N), and whether distant metastases exist (M). Pathologic stage is determined after surgical exploration and histologic examination of tissue, as opposed to clinical stage, which is estimated from imaging and physical exam before surgery.¹² Together, grade and stage form the backbone of prognosis and treatment planning.

Surgical Margins and Why They Matter

For patients undergoing surgery to remove a tumor, one of the most consequential parts of the pathology report is the margin status. The pathologist examines the edges of the excised tissue to determine whether tumor cells extend to the cut surface. A “negative” or “clear” margin means the nearest cancer cells are some distance from the edge; a “positive” margin means tumor cells are right at the ink line where the surgeon cut.

This distinction has real consequences. In breast-conserving surgery, patients with positive margins had a five-year local recurrence rate of 25%, compared with 5% for negative margins in one study of 150 patients.¹³ A large meta-analysis confirmed this pattern across many studies: tumor on the ink margin roughly doubled the risk of both local and distant recurrence, even after adjusting for whether the patient received chemotherapy and radiation.¹⁴ Positive margins often lead to re-excision surgery or a change in the radiation plan.

Special Stains and Immunohistochemistry

When H&E alone does not give enough information, pathologists reach for additional tools. Special histochemical stains use chemical reactions to highlight specific tissue components. Masson’s trichrome and Van Gieson stains pick out collagen, reticulin stains outline vascular architecture, and Alcian blue detects mucin-rich matrices.¹⁵ These stains help classify soft-tissue tumors, identify infectious organisms, and distinguish between look-alike conditions.

Immunohistochemistry (IHC) goes a step further. It uses antibodies that bind to specific proteins on or inside tumor cells, tagged with a colorimetric or fluorescent label so the pathologist can see whether the protein is present. IHC has become essential for classifying cancers of unknown origin, where a metastasis is found but the primary site is unclear. Systematic use of IHC panels can accurately classify most undifferentiated carcinomas while preserving tissue for any additional molecular testing that may be needed.¹⁶ In advanced gastric cancer, for example, standard IHC panels now routinely test for HER2, PD-L1, mismatch repair proteins, EBV, and CLDN18.2, each of which has implications for targeted therapy or immunotherapy eligibility.¹⁷

For poorly differentiated or undifferentiated tumors where IHC panels struggle, molecular gene-expression profiling can perform as well as or better than IHC at identifying the likely tissue of origin.¹⁸

Molecular Testing and Next-Generation Sequencing

Modern cancer pathology increasingly extends beyond what can be seen under a microscope. Molecular diagnostics interrogate the tumor’s DNA and RNA for mutations, gene fusions, and other alterations that influence prognosis and treatment choices. Next-generation sequencing (NGS) can screen dozens to hundreds of cancer-related genes simultaneously from a single formalin-fixed, paraffin-embedded tissue block.

Working with DNA from fixed tissue is challenging because formalin degrades nucleic acids, and the amount of tumor in any given sample varies. A comparison of two widely used NGS platforms found 100% concordance for somatic mutations in overlapping gene regions, including mutations present at low frequency. Combining both platforms in a workflow enabled successful molecular profiling of 96% of tumor samples and identified potentially actionable variants in about half of all cases.¹⁹ These actionable findings might include mutations that make a tumor eligible for a targeted drug or that indicate resistance to standard chemotherapy.

Artifacts and Pitfalls Along the Way

Every step in the pathology pipeline is a potential source of artifacts, alterations in the tissue that do not reflect biology but rather handling. Crushing the tissue during surgical removal, under-fixing or over-fixing, introducing air bubbles during embedding, cutting uneven sections on the microtome, or uneven staining can all distort what the pathologist sees.²⁰ Severe artifacts can render a specimen useless, forcing a repeat biopsy.²¹ Experienced pathologists learn to recognize common artifacts and mentally subtract them from their interpretation, but the risk of misdiagnosis rises when artifacts overlap with genuine abnormalities.

The Pathology Report

All of these findings ultimately coalesce into a written pathology report that goes to the treating clinician. Reports traditionally followed a narrative, free-text format. The problem with that approach is inconsistency: important data elements sometimes get left out. A shift toward template-based synoptic reporting, where the pathologist fills in a structured checklist of required elements, has markedly improved completeness. One study found that synoptic reports captured 98% of mandatory data elements, compared with 77% for narrative reports.²² A more recent real-world implementation in lung cancer pathology achieved 99.9% completeness with structured reporting and eliminated TNM classification errors that had appeared in conventional reports.²³ Pathologists adopted the tool voluntarily in over 90% of cases, suggesting it fits naturally into workflow.

How Long the Whole Process Takes

For patients, the wait between biopsy and diagnosis feels interminable. Routine biopsies average about three days from receipt to signed-out report, while complex cases push closer to five days.²⁴ At academic institutions, about three-quarters of specimens are finalized within two days, but the remaining quarter take three days or longer. The factors that most reliably extend turnaround time are a diagnosis of malignancy, the need for immunohistochemistry, consultation with other pathologists, and a high number of slides per case.²⁵ Molecular testing can add another week or more on top of that, meaning a patient whose tumor requires full NGS profiling may wait two to three weeks for the complete picture.

Quality-improvement efforts have targeted the bottlenecks. Slide allocation and delivery to pathologists, the review itself, transcription of the report, and final verification by the signing pathologist are where most delays cluster.²⁶ Digital slide scanning and electronic sign-out are increasingly common solutions, though they come with their own infrastructure costs.

Second Opinions and Diagnostic Disagreement

Cancer pathology is not as black-and-white as people imagine. Pathologists do disagree, especially in borderline cases. A study evaluating breast biopsy interpretation found an overall misclassification rate of about 25% on initial single-pathologist review. Having a second pathologist independently review the same slides lowered that rate to about 18%, and when both the first and second opinions came from pathologists who reviewed a high volume of breast biopsies weekly, the misclassification rate dropped to roughly 14%.²⁷ Atypia, the borderline category between normal and clearly abnormal, was the hardest to get right: more than half of atypia interpretations were discordant, and no second-opinion strategy brought that below about 34%.

In prostate cancer, second-opinion review of biopsies before surgery showed that outside referring pathologists’ grading was significantly less accurate compared to a final surgical specimen than in-house expert grading of the same biopsies, with undergrading more common than overgrading in both groups.²⁸ At a breast cancer multidisciplinary tumor board, pathology review changed the interpretation for 29% of referred patients, and 9% had their surgical management altered solely because of the pathologic reinterpretation.²⁹ These numbers are not cause for panic, but they are a strong argument for seeking expert review at a high-volume center when you face a complex or borderline diagnosis.

Liquid Biopsy as a Complement

A growing area of cancer diagnostics is the liquid biopsy: a blood draw analyzed for fragments of tumor DNA circulating in the bloodstream. The appeal is obvious. It is less invasive than cutting tissue, it can be repeated easily over time to track treatment response, and it can potentially capture genetic information from multiple tumor sites at once.

In prostate cancer, one study of patients with advanced disease found that a circulating tumor DNA assay identified about 94% of the somatic mutations found in matched metastatic tissue biopsies, with roughly 89% concordance for clinically actionable gene-level copy-number changes.³⁰ That is encouraging for a blood-based test. However, the picture is less tidy across cancer types more broadly. In the ROME trial, which enrolled patients with various advanced cancers being considered for targeted therapy, the overall concordance between tissue and liquid biopsy for actionable mutations was only about 49%. Roughly a third of actionable mutations were found exclusively in tissue, and about 16% were found exclusively in blood.³¹ The takeaway is that liquid biopsy and tissue biopsy are often complementary rather than interchangeable: each catches mutations the other misses, and relying on either one alone can leave actionable information on the table.

Artificial Intelligence Entering the Lab

Digital pathology, where glass slides are scanned into high-resolution whole-slide images, has opened the door for artificial intelligence tools. The FDA has approved whole-slide imaging scanners for primary diagnosis as well as an AI algorithm for prostate cancer grading, marking the first formal steps toward integrating machine learning into routine pathology.³² AI applications under development span tumor detection, grading, biomarker quantification, and prediction of molecular features directly from H&E images without additional lab tests.

These tools are not replacing pathologists. Instead, they function more like a spell-checker for slides: flagging areas of concern, pre-screening cases, and offering a second computational opinion. Given the diagnostic disagreement rates discussed earlier, an AI system that consistently applies the same criteria to every case could help reduce variability, especially in borderline categories where human interpretation wavers most. Adoption remains uneven, though. Most labs worldwide still rely on conventional microscopes, and the infrastructure needed for whole-slide scanning, digital storage, and AI deployment is a significant investment. The technology is promising, but the fully digital pathology lab is still a work in progress for most institutions.